Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating a fixed-dose combination of glycopyrronium and indacaterol/glycopyrronium bromide for COPD patients switching from standard regimens; c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Indacaterol (indacaterol)
• glycopyrronium (glycopyrronium)
• glycopyrronium bromide fixed-dose combination

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: COPD | Phase 4 | Status: COMPLETED | Results posted: 2019-03-19